Sacituzumab govitecan in HR+ and HER2- metastatic breast cancer: for all or for some?
Author:
Publisher
Elsevier BV
Subject
General Medicine
Reference11 articles.
1. Progression-free survival and overall survival of CDK 4/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and meta-analysis;Piezzo;Int J Mol Sci,2020
2. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer;Rugo;J Clin Oncol,2022
3. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial;Rugo;Lancet,2023
4. Informative censoring of progression-free survival data in the TROPiCS-02 trial: an unrecognized bias;Li;J Clin Oncol,2023
5. Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer;Meirson;Lancet Oncol,2023
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Enhancing Antitumor Activity of Herceptin in HER2-Positive Breast Cancer Cells: A Novel DNMT-1 Inhibitor Approach;2024-09-02
2. Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial;The Lancet;2024-07
3. Biomarkers for Antibody–Drug Conjugates in Solid Tumors;Molecular Cancer Therapeutics;2024-02-02
4. Single-cell and spatial transcriptome sequencing uncover a platinum-resistant cluster overexpressed TACSTD2 in high-grade serous ovarian cancer;Journal of Cancer;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3